Stellate Ganglion Block for Refractory Coronary Artery Spasm
In patients with documented coronary artery spasm refractory to maximum-tolerated calcium channel blockers and nitrates, stellate ganglion block (SGB) is a reasonable rescue intervention, though it is not formally endorsed in major guidelines and should be considered only after exhausting all pharmacologic options including alpha-blockers.
Guideline-Based Treatment Algorithm
First-Line Therapy (Class I Evidence)
The ACC/AHA guidelines establish that calcium channel blockers and long-acting nitrates are first-line therapies for coronary artery spasm 1, 2, 3. Standard dosing includes:
- Verapamil 240-480 mg/day
- Diltiazem 180-360 mg/day
- Nifedipine 60-120 mg/day
Patients with very active disease require combination therapy with nitrates plus two different classes of calcium channel blockers (e.g., a dihydropyridine with verapamil or diltiazem) 1.
Second-Line Options
When patients fail to respond completely to calcium channel blockers and nitrates, alpha-receptor blockers have been reported to provide benefit 1. This should be attempted before considering invasive sympathetic interventions.
Refractory Cases: The Role of Cardiac Denervation
The guidelines acknowledge that treatment can be "very frustrating in the occasional patient refractory to standard medication" and note that "cardiac denervation has been used in these patients with marginal benefit" 2, 1. This represents the only guideline-level mention of sympathetic intervention, though it carries no formal recommendation class.
Stellate Ganglion Block: Evidence and Technique
When to Consider SGB
SGB should be considered when:
- Maximum-tolerated doses of calcium channel blockers have failed
- Combination therapy with nitrates and multiple calcium channel blocker classes has failed
- Alpha-blockers have been tried without adequate response
- Life-threatening complications occur (recurrent cardiac arrest, electrical storm, hemodynamic instability)
Evidence Base
Recent case reports demonstrate SGB efficacy in refractory coronary spasm:
- Successful termination of multivessel spasm with cardiac arrest requiring ECMO support, with subsequent decannulation after left SGB 4
- Prevention of recurrent spasm in a patient with eosinophilic asthma-related spasm, using unilateral SGB as bridge to bilateral thoracoscopic sympathectomy 5
- 100% success rate in terminating sympathetically-mediated arrhythmias post-MI in a 5-patient series 6
Recommended Technique
Approach: Ultrasound-guided technique is preferred over classical anatomic landmarks 7, 6
Target: Left stellate ganglion (C6-T1 level) is the primary target, as it contains the majority of postganglionic sympathetic fibers innervating the AV node, bundle of His, and ventricular mass 7
Medication: 1% lidocaine hydrochloride (typical volumes 5-10 mL) 6
Laterality:
- Start with left-sided block for most cases 4, 7
- Bilateral blocks may be needed for refractory cases 5, 6
Monitoring Requirements
Immediate confirmation:
- Development of ipsilateral Horner syndrome (ptosis, miosis, anhidrosis) confirms successful sympathetic blockade 6
Continuous monitoring:
- Continuous ECG monitoring during and after procedure
- Blood pressure monitoring for hypotension
- Observation for pneumothorax (rare with ultrasound guidance)
- Monitor for recurrence of spasm/arrhythmia
Duration of effect:
- Temporary (hours to days with local anesthetic alone)
- May serve as bridge to definitive surgical sympathectomy if effective 5, 8
Critical Caveats
High-Risk Features Requiring Caution
The guidelines explicitly state that provocative testing (and by extension, invasive procedures) should be avoided in patients with 3:
- Significant left main disease
- Advanced 3-vessel disease
- High-grade obstructive lesions
- Significant valvular stenosis
- Significant LV systolic dysfunction
- Advanced heart failure
Contraindications to Beta-Blockers
Beta-blockers are contraindicated in vasospastic angina as they can precipitate spasm by leaving α-mediated vasoconstriction unopposed 3, 9. This underscores the sympathetic mechanism that SGB targets.
Procedure-Specific Risks
- Pneumothorax (minimized with ultrasound guidance)
- Vascular injury
- Recurrent laryngeal nerve block
- Phrenic nerve block
- Intravascular injection
- Seizure from local anesthetic toxicity
Bridge to Definitive Therapy
If SGB provides temporary relief, consider bilateral thoracoscopic sympathectomy as definitive treatment 5. This has shown sustained benefit in case reports of truly refractory spasm, though it represents an extreme measure with permanent autonomic consequences.
Prognosis Context
The guidelines note that prognosis is generally excellent with medical therapy (89-97% 5-year survival), particularly in patients with normal or near-normal coronary arteries 2, 1. However, patients with spasm superimposed on obstructive CAD have worse outcomes (80% 5-year survival with multivessel disease) 2. This risk stratification should inform the aggressiveness of intervention.
The decision to proceed with SGB represents a salvage therapy for a small subset of patients who have exhausted all guideline-recommended pharmacologic options and face life-threatening recurrent spasm.